Cargando…
Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma
The heterogeneous polyclonal nature of multiple myeloma complicates the identification of protein biomarkers predictive of drug response. In this study, a pharmacodynamic systems modeling approach was used to link in vitro bortezomib exposure and myeloma cell death. The exposure‐response was integra...
Autores principales: | Ramakrishnan, Vidya, Mager, Donald E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430155/ https://www.ncbi.nlm.nih.gov/pubmed/30516019 http://dx.doi.org/10.1002/psp4.12358 |
Ejemplares similares
-
Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2013) -
Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009) -
Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006) -
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020) -
Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)